A microRNA diagnostic biomarker for amyotrophic lateral sclerosis

Key points

Investigates a new mRNA test to diagnose ALS

Affiliates

Sandra Anne Banack [1], Rachael A Dunlop [1], Paul Mehta [2], Hiroshi Mitsumoto [3], Stewart P Wood [1], Moon Han [2], Paul Alan Cox [1]

  1. Brain Chemistry Labs, Jackson, WY 83001, USA
  2. Office of Innovation and Analytics, Agency for Toxic Substances and Disease Registry, Centers for Disease Control and Prevention, Atlanta, GA 30033, USA
  3. Eleanor and Lou Gehrig MND/ALS Research Center, Department of Neurology, Columbia University Medical Center, New York, NY 10032, USA

Journal

Brain Communications

Summary

This paper from Brain Chemistry Labs aims to propose a new blood test for amyotrophic lateral sclerosis (ALS). It discusses the challenges of diagnosing ALS and the need for better biomarkers. The authors propose an eight-microRNA signature test using extracellular vesicles in blood plasma. They found this test to be accurate in identifying ALS patients. This test could aid in earlier diagnosis and improve patient outcomes.

Link to paper

Read the full paper here!

Print
Content Source:
Agency for Toxic Substances and Disease Registry